Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
In the last 90 days, Nuvectis Pharma, Inc. insiders filed 2 open-market purchases and 0 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Nuvectis Pharma, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- 0 vs. Q3 2022
- Shares held
- 983.9K
- +129.2K (+15.1%) vs. Q3 2022
- Total value
- $7.38M
- +$1.32M (+21.7%) vs. Q3 2022
- New holders
- 2
- 4 more added
- Sold out
- 2
- 4 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NVCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 82 | $189.0M |
| Q1 2026 | 62 | $34.9M |
| Q4 2025 | 48 | $32.0M |
| Q3 2025 | 53 | $22.2M |
| Q2 2025 | 47 | $24.2M |
| Q1 2025 | 33 | $20.0M |
| Q4 2024 | 31 | $7.15M |
| Q3 2024 | 31 | $6.60M |
| Q2 2024 | 41 | $7.63M |
| Q1 2024 | 40 | $12.8M |
| Q4 2023 | 36 | $12.6M |
| Q3 2023 | 33 | $16.5M |
| Q2 2023 | 37 | $20.0M |
| Q1 2023 | 13 | $6.34M |
| Q4 2022 | 11 | $7.38M |
| Q3 2022 | 12 | $10.0M |
| Q2 2022 | 11 | $7.20M |
| Q1 2022 | 8 | $4.65M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Nuvectis Pharma, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 587,452 | $4.41M | 11.80% | −45,527−7.2% | Reduced |
| Vanguard Group Inc | 195,829 | $1.47M | 0.00% | +168,768+623.7% | Added |
| Baldwin Brothers Inc | 133,300 | $999.8K | 0.09% | +300+0.2% | Added |
| Geode Capital Management, LLC | 31,368 | $235.0K | 0.00% | −73−0.2% | Reduced |
| Virtu Financial LLC | 12,418 | $93.0K | 0.01% | +12,418 | New |
| State Street Corp | 11,700 | $87.9K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 10,161 | $76.2K | 0.00% | −3,842−27.4% | Reduced |
| Tower Research Capital LLC (TRC) | 1,359 | $10.0K | 0.00% | −2,693−66.5% | Reduced |
| Morgan Stanley | 301 | $2.26K | 0.00% | +100+49.8% | Added |
| Wells Fargo & Company | 25 | $188 | 0.00% | +1+4.2% | Added |
| Bank of America Corp | 12 | $90 | 0.00% | +12 | New |
| UBS Group AG | 0 | $0 | 0.00% | −220−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −76−100.0% | Sold out |
| Ronit Capital LLP | – | – | – | – | Not filed |